positive clinical data with no marked side effects suggests this will most likely be an approved drug in the treatment of pancreatic cancer - subject to continuation of this positive trend
directors putting their money in
institutional interest suggest great potential - especially the raise is after a significant rise in share price
positive clinical data with no marked side effects suggests this...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $93.52M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 23.0¢ | $1.394M | 5.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 580668 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 20109 | 1 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |